A Multinational, Multicenter, Open-Label Phase II Study of SyB L-0501 in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Trial Profile

A Multinational, Multicenter, Open-Label Phase II Study of SyB L-0501 in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2015

At a glance

  • Drugs Bendamustine (Primary) ; Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors SymBio Pharmaceuticals
  • Most Recent Events

    • 10 Feb 2015 According to a SymBio Pharmaceuticals media release, this phase II trial generated positive data. The company will continue to pursue approval for refractory/relapsed intermediate/high-grade non-Hodgkin's lymphoma.
    • 01 Jun 2012 Resutls presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to a SymBio Pharmaceuticals media release.
    • 01 Jun 2012 Status changed from unconfirmed to completed, according to a SymBio Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top